S. Mori

Salvage nivolumab and ipilimumab after prior anti‐PD‐1/PD‐L1 therapy in metastatic renal cell carcinoma: A meta‐analysis

M. Yin, M. Hinkley, Yuanquan Yang, 2022, Cancer medicine.

Combining immune checkpoint inhibition plus tyrosine kinase inhibition as first and subsequent treatments for metastatic renal cell carcinoma

S. Psutka, M. Yin, John A Thompson, 2022, Cancer medicine.

Serum free light chains in myeloma patients with an intact M protein by immunofixation: potential roles for response assessment and prognosis during induction therapy with novel agents

C. Hofmeister, G. Phillips, D. Benson, 2012, Hematological oncology.

[Development of sandwich radioimmunometric assay for serum c-erbB-2 oncogene product and its significance in diagnosing breast carcinoma].

K. Sugano, H. Ohkura, F. Yu, 1991, Rinsho byori. The Japanese journal of clinical pathology.

[Clinical evaluation of serum ErbB-2 protein using enzyme immuno assay (ErbB-2 EIA [Nichirei])].

K. Sugano, T. Nakayama, R. Demura, 1994, Gan to kagaku ryoho. Cancer & chemotherapy.

[Clinical study of serum ErbB-2 protein using sandwich radioimmunometric assay (ErbB-2 IRMA 'Eiken')].

K. Sugano, T. Nakayama, R. Demura, 1994, Gan to kagaku ryoho. Cancer & chemotherapy.

Serum free light chains in myeloma patients with an intact M protein by immunofixation: potential roles for response assessment and prognosis during induction therapy with novel agents

C. Hofmeister, G. Phillips, D. Benson, 2012, Hematological oncology.